Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gianolio

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Chemmedchem|March 9, 2018
Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug ConjugatesBo Chen, Diego A Gianolio, James E Stefano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional ChondrosarcomaWilliam D Tap, Gregory M Cote, Howard Burris, et al.
Organic & Biomolecular Chemistry|August 29, 2019
Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugationKanwen Yang, Bo Chen, Diego A Gianolio, et al.
Molecular Cancer Therapeutics|July 18, 2015
Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other MalignanciesCecile Rouleau, Diego A Gianolio, Robert Smale, et al.
Bioconjugate Chemistry|August 23, 2008
Hyaluronan-tethered opioid depots: synthetic strategies and release kinetics in vitro and in vivoDiego A Gianolio, Michael Philbrook, Luis Z Avila, et al.
The Journal of Clinical Investigation|June 2, 2020
Taxane resistance in prostate cancer is mediated by decreased drug-target engagementAda Gjyrezi, Fang Xie, Olga Voznesensky, et al.
The New England Journal of Medicine|April 20, 2022
Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid LeukemiaPau Montesinos, Christian Recher, Susana Vives, et al.
Cancer Chemotherapy and Pharmacology|July 24, 2012
Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugatesDiego A Gianolio, Cecile Rouleau, William E Bauta, et al.
Bioconjugate Chemistry|February 19, 2014
Site-specific antibody-drug conjugation through glycoengineeringQun Zhou, James E Stefano, Charlene Manning, et al.
Blood Advances|July 24, 2025
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AMLPau Montesinos, Dylan M Marchione, Christian Récher, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Chemmedchem|March 9, 2018
Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug ConjugatesBo Chen, Diego A Gianolio, James E Stefano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional ChondrosarcomaWilliam D Tap, Gregory M Cote, Howard Burris, et al.
Organic & Biomolecular Chemistry|August 29, 2019
Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugationKanwen Yang, Bo Chen, Diego A Gianolio, et al.
Molecular Cancer Therapeutics|July 18, 2015
Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other MalignanciesCecile Rouleau, Diego A Gianolio, Robert Smale, et al.
Bioconjugate Chemistry|August 23, 2008
Hyaluronan-tethered opioid depots: synthetic strategies and release kinetics in vitro and in vivoDiego A Gianolio, Michael Philbrook, Luis Z Avila, et al.
The Journal of Clinical Investigation|June 2, 2020
Taxane resistance in prostate cancer is mediated by decreased drug-target engagementAda Gjyrezi, Fang Xie, Olga Voznesensky, et al.
The New England Journal of Medicine|April 20, 2022
Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid LeukemiaPau Montesinos, Christian Recher, Susana Vives, et al.
Cancer Chemotherapy and Pharmacology|July 24, 2012
Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugatesDiego A Gianolio, Cecile Rouleau, William E Bauta, et al.
Bioconjugate Chemistry|February 19, 2014
Site-specific antibody-drug conjugation through glycoengineeringQun Zhou, James E Stefano, Charlene Manning, et al.
Blood Advances|July 24, 2025
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AMLPau Montesinos, Dylan M Marchione, Christian Récher, et al.
Pageof 4